Shacham Sharon's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Mar 2, 2022
- Accession no.
- 0001209191-22-014626
- Filed
- Mar 2, 2022
- Trade date
- Feb 28, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $127.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shacham SharonCIK 0001588438 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | SSaleDisposed | −6,226 | $10.24F2 | −$63,754.24 | 898,131 | Direct | Duplicate filing |
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +21,000 | $0.00 | $0 | 719,983 | Indirect | Duplicate filing |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −6,226 | $10.24F2 | −$63,754.24 | 713,757 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +27,000 | $0.00 | $0 | 27,000 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 2 transactions in Table I.